Ultragenyx Pharmaceutical Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Ultragenyx Pharmaceutical Inc. on June 24, 2021. The filing details the voting results for three proposals submitted to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
As of the record date (April 26, 2021), 67,474,643 shares were outstanding. A total of 65,546,806 shares were represented at the meeting. The voting results were as follows:
- Proposal 1 (Election of Class II Directors):
- Deborah Dunsire, M.D.: Elected with 62,938,341 votes for.
- Michael Narachi: Elected with 46,632,516 votes for (17,199,662 votes withheld).
- Proposal 2 (Ratification of Accounting Firm):
- Ernst & Young LLP was ratified with 65,447,126 votes for.
- Proposal 3 (Advisory Vote on Executive Compensation):
- Approved with 47,341,635 votes for (16,454,026 votes against).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Michael Narachi received a significant number of withheld votes (approx. 27% of votes cast on his nomination) compared to the other director nominee.
- Executive compensation received a "say-on-pay" vote with approximately 25% of votes cast against the proposal.
- Ernst & Young LLP was confirmed as the independent auditor for the fiscal year ending December 31, 2021.
- Shareholder participation was high, with approximately 97% of outstanding shares represented at the meeting.